| Abstrakt: |
This study aimed to evaluate the impact of ascidian-derived plasmalogen on cognitive function in healthy humans without suspicion of MCI (Mild Cognitive Impairment) with MMSE (Mini-Mental State Examination) scores of >28. We reanalyzed the results of a randomized, double-blind, placebo-controlled study of the impact on cognitive function of ascidian-derived plasmalogen in healthy subjects (MMSE >24). Participants in this trial consumed either an active food containing ascidian-derived plasmalogen or a placebo for 12 weeks, and their cognitive performance was assessed by Cognitrax, DASC-21 (Dementia Assessment Sheet in Community-based Integrated Care System), and a subjective symptom questionnaire. In the results, compared to the placebo group, the intervention group exhibited a significant increase in their Cognitrax composite memory score, indicating that consumption of ascidian-derived plasmalogen maintains and enhances cognitive function. We re-analyzed data from selected participants in this clinical trial without suspicion of MCI with MMSE scores of >28. Targets of analysis in the intervention and placebo group numbered 19 (6 male, and 13 female; mean age, 46.1士 10.2 years) and 22 (7 male, and 15 female; mean age, 45.8士 11.1 years), respectively. Changes in composite memory score were significantly higher at 8 and 12 weeks (P = 0.043，P = 0.016, respectively) after intake in the intervention group compared with those in the placebo group. Ingestion of ascidian-derived plasmalogen for 12 weeks was shown to be effective for memory function even for healthy subjects without suspicion of MCI with MMSE scores of ≥28. [ABSTRACT FROM AUTHOR] |
